http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105510467-A
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a1e96f9c1e753727fc5529a6b974143b http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_039ffe7178c059774da2fd143d6dae70 |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2030-027 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5008 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-546 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N30-02 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N30-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-546 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 |
filingDate | 2015-12-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bfb26aef30d9da62a81ba55a23872f75 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3124a589f8401fd1c631c2e8ec7ce8d0 |
publicationDate | 2016-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | CN-105510467-A |
titleOfInvention | Application of preclinical pharmacokinetic key technology and research system in ceftizoxime sodium |
abstract | The invention provides application of a preclinical pharmacokinetic key technology and research system in ceftizoxime sodium, comprising the steps of (1) after the ceftizoxime sodium with a certain concentration is administrated to an experimental animal for a certain time, collecting one or more biological samples in blood, urine and faeces; (2) treating the biological samples obtained in step (1) by adopting liquid-liquid extraction, albumen precipitation, and solid phase extraction technologies to obtain a corresponding solution; (3) analyzing the prepared solution in step (2) by adopting an LC-MS(liquid chromatography-mass spectrography) and an LC-MS/MS((liquid chromatography-tandem mass spectrometry). According to the application provided by the invention, the Caco-2 cell can also be adopted to detect the membrane permeability of the medicine and cell absorptive capacity; or the medicine with a certain concentration treats primary culture cerebral microvascular endothelial cells to detect the blood-brain barrier permeability of the medicine; or by adopting a whole animal, S9, human intestinal microsome and monoclonal purified enzyme, in vitro metabolism stability of the medicine is detected and a metabolite is identified. |
priorityDate | 2015-12-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 283.